How should urine drug testing be billed (80305 vs G0480 to G0483)?

What is the difference between 80305, 80306 and 80307?

CPT 80305, 80306 and 80307 are the three presumptive drug testing codes, and the only thing that separates them is how the result is read, not how many drugs you test for. Each code covers any number of drug classes and any number of devices, and each is reported once per patient per date of service.

• 80305: cups, dipsticks, cards or cartridges read by direct optical observation only. This is the urine drug screen CPT code most physician offices use. It is the only presumptive code that runs under a CLIA Certificate of Waiver, and Medicare wants modifier QW on it when a waived kit is used.
• 80306: the same kind of device, but read by an instrument that assists the optical read, such as a cup reader. It needs a non-waived CLIA certificate.
• 80307: presumptive testing on instrument chemistry analyzers, such as immunoassay on a chemistry platform. It is the highest-paying presumptive code and also needs a non-waived certificate.

The code follows the method, so a 12-panel cup and a 5-panel cup are both 80305 with one unit. Adding panels does not add units. Billing one unit per drug class is the single most common presumptive error we see, and it produces duplicate or units denials on every claim it touches.

When do you bill G0480 to G0483 instead of 80320 to 80377?

Bill G0480 to G0483 for definitive drug testing on Medicare claims, because CMS does not recognize CPT 80320 to 80377 and created the G codes in 2016 to replace per-class billing. Definitive testing identifies specific drugs and metabolites with methods such as GC-MS or LC-MS/MS, and it is priced by how many drug classes the lab reports that day.

• G0480: 1 to 7 drug classes, including metabolites
• G0481: 8 to 14 drug classes
• G0482: 15 to 21 drug classes
• G0483: 22 or more drug classes
• G0659: definitive testing run without drug-specific calibration and without matrix-matched quality control, any number of classes

Commercial and Medicaid plans split. Some accept CPT 80320 to 80377, billed per drug class, while others follow Medicare. UnitedHealthcare Medicare Advantage, for example, treats 80320 to 80377 as non-reimbursable and requires G0480 to G0483 or G0659. Set the definitive code set per payer in your charge master before the first claim goes out, then let the claim scrubber enforce it. Our medical coding team builds that payer map as part of onboarding.

The pay gap between tiers is large. In 2026, Medicare pays $12.60 for 80305, $17.14 for 80306 and $62.14 for 80307, then $114.43 for G0480, $156.59 for G0481, $198.74 for G0482 and $246.92 for G0483. These rates have held since 2020 because Congress kept delaying PAMA cuts, including for the rest of 2026.

How do you count drug classes to pick G0480, G0481, G0482 or G0483?

Count the drug classes the lab actually tested and reported for that patient on that date of service, using the class definitions in the CPT definitive drug testing section, and pick the one G code whose range contains that count. Metabolites and multiple drugs within one class do not add classes. Here is the step list we use on every definitive claim:

1. Start from the order. The provider’s order must name the drugs or classes for this patient, based on history, current medications and risk. A panel box ticked for every patient is not an individualized order.
2. List the classes on the final report, not the classes on the requisition. If the lab cancels a class for specimen problems, it does not count.
3. Group drugs into classes. A parent drug and its metabolite count as one class, such as oxycodone and noroxycodone, and two benzodiazepines count as one benzodiazepine class.
4. Map the count to the tier. Six classes is G0480. Eight is G0481. Never bill the next tier for a count below it.
5. Bill one unit of one G code for the date of service, even if the specimen was run twice or split across two instruments.
6. Attach the diagnosis that supports the order, such as Z79.891 for long-term opioid use or the F11 to F19 code for the substance use disorder being monitored.

The OIG has watched this step closely. Its February 2023 audit found that 1,062 providers billed G0483 for 75% or more of their definitive tests and were paid $704.2 million from 2016 to 2020, against a G0483 share of 21.2% for everyone else. The OIG estimated Medicare could have saved $215.8 million over five years. If most of your definitive claims land on G0483, expect the order documentation to be pulled.

Can you bill 80307 and G0480 on the same day?

Yes. Medicare allows one presumptive code and one definitive code for the same patient on the same date of service, each with one unit, as long as both tests are separately ordered and medically necessary. The 2026 Medicare NCCI Policy Manual limits each family to one code per date of service; it does not bar the two families together.

This question comes up because of a July 2023 NCCI edit that briefly paired 80305 to 80307 with G0480 to G0483 and G0659 and denied the definitive line. CMS withdrew that edit retroactive to July 1, 2023, and reprocessed the affected claims.

Two limits still apply on the same day:

• One of each, per patient, across all providers. WPS billing article A56915 says one presumptive code may be billed once per patient per day at one unit regardless of the provider. If the clinic runs a cup and a reference lab also runs an immunoassay screen, only one presumptive line gets paid.
• No automatic reflex. LCD L35724 does not cover reflex definitive testing when the presumptive test was done at the point of care, unless the provider orders it for that patient based on the result.

How often will Medicare pay for urine drug testing?

Medicare pays for urine drug testing only as often as the local coverage determination allows for the patient’s situation, and the limits in LCD L35724 and LCD L36029 are specific. For substance use disorder treatment:

• 0 to 30 days of abstinence: 3 presumptive tests and 1 definitive test in a rolling 7 days
• 31 to 90 days: 3 presumptive tests in a rolling 7 days and 3 definitive tests in a rolling 30 days
• Over 90 days: 3 presumptive tests in a rolling 30 days and 3 definitive tests in a rolling 90 days

For chronic opioid therapy the limits follow the patient’s risk level: 2 presumptive and 2 definitive tests in a rolling 365 days at low risk, 2 each in 180 days at moderate risk, and 3 each in 90 days at high risk. Other MACs publish their own LCDs, and Novitas LCD L35006 uses calendar-year counts instead, so confirm which LCD covers your state. Tests beyond the limit need an Advance Beneficiary Notice signed before the specimen is collected, or the practice absorbs the cost.

Medicaid plans often set annual caps. One Louisiana Medicaid plan, for instance, limits members to 24 presumptive and 12 definitive tests per calendar year and one of each per date of service. Load those caps into your scheduling rules so the front desk sees them before collection, which is the same logic our eligibility and prior authorization team uses for every frequency-limited service.

What does drug testing pay for one patient? A worked example

Take an outpatient addiction medicine clinic with a moderate complexity lab: an immunoassay chemistry analyzer for screens and an LC-MS/MS instrument for confirmation. It treats 60 Medicare patients in their first 30 days of abstinence and tests at the LCD maximum.

• Presumptive: 3 tests a week for 4 weeks is 12 tests. 12 x $62.14 (80307) = $745.68 per patient.
• Definitive, individualized: 1 test a week for 4 weeks, with orders naming 6 drug classes. 4 x $114.43 (G0480) = $457.72 per patient.
• Definitive, blanket panel: the same 4 tests run on a 25-class panel for everyone. 4 x $246.92 (G0483) = $987.68 per patient.

Billed correctly, each patient generates $745.68 + $457.72 = $1,203.40 over four weeks, or $72,204.00 across 60 patients. The blanket panel bills $529.96 more per patient, which is $31,797.60 a month across the clinic. That extra $31,797.60 is exactly the money an OIG or MAC audit targets when the orders are not individualized, and recoupment usually reaches back years, not months. If the clinic used 80305 cups instead of the analyzer, presumptive revenue would fall to 12 x $12.60 = $151.20 per patient, which is why method choice belongs in the lab business plan, not just the coding step.

Per patient over four weeks, 12 screens on 80307 bill $745.68, four G0480 tests bill $457.72, four G0483 tests bill $987.68, and the G0483 gap is $529.96.

What urine drug test billing mistakes cause denials?

Most drug testing denials come from units, orders and payer rules, not from picking the wrong tier. Across all specialties in the Luxen claim audit, eligibility and coverage errors caused 24% of denials, coding and modifier errors caused 21% of denials, and duplicate claim denials made up 9% of denials, mostly from resubmitting instead of correcting. Drug testing concentrates the last two.

The mistakes we fix most often on drug testing claims:

1. More than one unit. 80305 to 80307 and G0480 to G0483 are one unit per date of service. Billing units per class or per device fails the medically unlikely edit.
2. Standing or blanket orders. LCD L35724 and LCD L36029 both call routine standing orders for all patients not reasonable and necessary. A signed protocol is not an order.
3. Billing specimen validity testing. pH, specific gravity, oxidants and creatinine checks are part of the drug test. The NCCI manual says validity testing on urine is not billed separately.
4. Missing QW on 80305. A waived cup billed without QW is rejected on Medicare claims.
5. Wrong code set for the payer. Sending 80320 to 80377 to Medicare, or G codes to a plan that pays per class, denies the whole definitive line.
6. Missing or invalid ordering provider. Ordering provider NPI was missing or invalid on 9% of lab claims in our audit. On drug testing, that one field decides whether the claim is even processed.
7. Letting small denials go. 19% of denied claims were never reworked or appealed in the billing reviews we ran. At $62.14 a screen, those write-offs feel small until you multiply them by three tests a week.

Appeals work when the order is documented. Appeals filed by Luxen were overturned 68% of the time. Our denials and AR recovery team works drug testing denials by root cause, so one fix clears the whole batch instead of one claim.

Should you bill drug tests in-house or send them to a reference lab?

The entity that performs the test bills it. If your office runs the cup or the analyzer, you bill 80305 to 80307 under your CLIA certificate. If you send the specimen to a reference lab, the lab bills the definitive G code and you bill nothing for that test. Medicare requires the lab that performs a clinical lab test to bill it directly.

Running a lab in-house makes sense when test volume covers the instrument, the certificate, proficiency testing and a biller who knows the LCDs. Point-of-care cups with a waiver are cheap to run but pay $12.60. An analyzer pays $62.14 but needs a moderate complexity certificate and staff. In-house LC-MS/MS adds the definitive revenue and the audit exposure that comes with it. For deeper coverage of lab setups, see our pages on toxicology billing services and laboratory billing.

Outsourcing the billing is a separate choice from outsourcing the test. A billing company typically charges 3% to 6% of collections and should bring LCD frequency rules, payer code sets and order checks on day one. Whichever way you go, compare the fee against what denials already cost you. Full-service medical billing covers the whole claim cycle, and a free billing review will show where your drug testing claims are leaking before you decide.

80305 vs 80307 vs G0480 to G0483: which code fits which test?

Presumptive codes follow the testing method and definitive codes follow the number of drug classes reported. Every code in the table is one unit per patient per date of service, except the per-class CPT definitive codes that Medicare does not accept.

Addiction treatment and opioid treatment programs

This is where G0480 to G0483 volume and audit risk concentrate. Medicare opioid treatment programs are paid a weekly bundle that already includes toxicology testing under 42 CFR 410.67, so an OTP cannot bill 80305 to 80307 or G0480 to G0483 separately for bundled patients. Office-based addiction practices and residential programs can bill them, within the LCD frequency limits for 0 to 30, 31 to 90 and over 90 days of abstinence. Each definitive order needs the classes named for that patient. More on program billing is on our substance abuse billing page.

Pain management

Chronic opioid therapy drives testing here, and the LCD limits follow the documented risk level: 2 tests of each type in a rolling 365 days at low risk, 180 days at moderate risk, and 3 in 90 days at high risk. Put the risk tool score in the note, pair the claim with Z79.891, and send definitive testing only when the screen is unexpected or the drug is not detectable by immunoassay. Our pain management billing team checks those limits before collection.

Primary care

Most primary care offices run waived cups under a Certificate of Waiver and bill 80305 with QW, once per visit, for patients on long-term opioids or benzodiazepines. Confirmation goes to a reference lab, which bills the G code itself. The common miss is adding a second unit for a second cup on the same day. See how this fits the wider claim cycle on our primary care billing page.

Behavioral health

Psychiatrists and group practices treating co-occurring disorders usually collect in office and send specimens out. Unless the practice holds a CLIA certificate and runs the test, it bills no drug test code. Therapists and counselors do not bill drug testing at all. Behavioral health carve-out plans may not cover lab work, so route the lab claim to the medical plan.

Dental, physical therapy and ambulance

Dental offices, physical therapy clinics and ambulance services do not bill urine drug testing to health plans. Pre-employment, DOT and workplace screens for staff are not medically necessary services and are paid by the employer, never billed to the employee’s insurance.